Please use this identifier to cite or link to this item:
Title: Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Authors: BETTEGOWDA, ChetanSAUSEN, MarkLEARY, Rebecca J.KINDE, IsaacWANG, YuxuanAGRAWAL, NishantBARTLETT, Bjarne R.WANG, HaoLUBER, BrandonALANI, Rhoda M.ANTONARAKIS, Emmanuel S.AZAD, Nilofer S.BARDELLI, AlbertoBREM, HenryCAMERON, John L.LEE, Clarence C.FECHER, Leslie A.GALLIA, Gary L.GIBBS, PeterLE, DungGIUNTOLI, Robert L.GOGGINS, MichaelHOGARTY, Michael D.HOLDHOFF, MatthiasHONG, Seung-MoJIAO, YuchenJUHL, Hartmut H.KIM, Jenny J.SIRAVEGNA, GiuliaLAHERU, Daniel A.LAURICELLA, CalogeroLIM, MichaelLIPSON, Evan J.MARIE, Suely Kazue NagahashiNETTO, George J.OLINER, Kelly S.OLIVI, AlessandroOLSSON, LouiseRIGGINS, Gregory J.SARTORE-BIANCHI, AndreaSCHMIDT, KerstinSHIH, Ie-MingOBA-SHINJO, Sueli MiekoSIENA, SalvatoreTHEODORESCU, DanTIE, JeanneHARKINS, Timothy T.VERONESE, SilvioWANG, Tian-LiWEINGART, Jon D.WOLFGANG, Christopher L.WOOD, Laura D.XING, DongmeiHRUBAN, Ralph H.WU, JianALLEN, Peter J.SCHMIDT, C. MaxCHOTI, Michael A.VELCULESCU, Victor E.KINZLER, Kenneth W.VOGELSTEIN, BertPAPADOPOULOS, NickolasDIAZ JR., Luis A.
Citation: SCIENCE TRANSLATIONAL MEDICINE, v.6, n.224, 2014
Abstract: The development of noninvasive methods to detect and monitor tumors continues to be a major challenge in oncology. We used digital polymerase chain reaction-based technologies to evaluate the ability of circulating tumor DNA (ctDNA) to detect tumors in 640 patients with various cancer types. We found that ctDNA was detectable in > 75% of patients with advanced pancreatic, ovarian, colorectal, bladder, gastroesophageal, breast, melanoma, hepatocellular, and head and neck cancers, but in less than 50% of primary brain, renal, prostate, or thyroid cancers. In patients with localized tumors, ctDNA was detected in 73, 57, 48, and 50% of patients with colorectal cancer, gastroesophageal cancer, pancreatic cancer, and breast adenocarcinoma, respectively. ctDNA was often present in patients without detectable circulating tumor cells, suggesting that these two biomarkers are distinct entities. In a separate panel of 206 patients with metastatic colorectal cancers, we showed that the sensitivity of ctDNA for detection of clinically relevant KRAS gene mutations was 87.2% and its specificity was 99.2%. Finally, we assessed whether ctDNA could provide clues into the mechanisms underlying resistance to epidermal growth factor receptor blockade in 24 patients who objectively responded to therapy but subsequently relapsed. Twenty-three (96%) of these patients developed one or more mutations in genes involved in the mitogen-activated protein kinase pathway. Together, these data suggest that ctDNA is a broadly applicable, sensitive, and specific biomarker that can be used for a variety of clinical and research purposes in patients with multiple different types of cancer.
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MNE
Departamento de Neurologia - FM/MNE

Artigos e Materiais de Revistas Científicas - LIM/15
LIM/15 - Laboratório de Investigação em Neurologia

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar

Files in This Item:
File Description SizeFormat 
  Restricted Access
publishedVersion (English)1.44 MBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.